GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events

ME Staff 8-k
-
0

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events.

On March5, 2018, GTx,Inc. issued a press release announcing additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence, including magnetic resonance imaging results from patients’ pelvic floor muscle.

A copy of the press release is furnished as Exhibit99.1 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued by GTx,Inc. dated March5, 2018


GTX INC /DE/ Exhibit
EX-99.1 2 a18-7430_1ex99d1.htm EX-99.1 Exhibit 99.1   GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence at SUFU 2018   — MRI results show increases in pelvic floor muscle and urethral muscle diameter supporting enobosarm’s mechanism of action —   — Additional positive results in subset of postmenopausal women suggest dual treatment effect on urge incontinence and stress urinary incontinence —   — Top-line results for a Phase 2 placebo-controlled clinical trial expected in the second half of 2018 —   MEMPHIS,…
To view the full exhibit click here

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.